Feb
10
The European Union funds research on the pandemic threats of Dengue (DENV) and West Nile Virus (WNV)
Strengthening the EU's capacity to combat DENV and WNV epidemics and pandemic threats is necessary to develop effective contingency plans. For this reason, the EU has funded the international project InFlaMe (Grant Agreement ID: 101191725), which is based on three pillars: 1) the clinical investigation of factors related to serious disease 2) the development of [...]
DETAIL
Feb
04
CheckmAb’s Immunotherapy in Collaboration with Boehringer Ingelheim Advances to Next Stage
CheckmAb’s Immunotherapy in Collaboration with Boehringer Ingelheim Advances to Next Stage Milan, Italy, February 4th 2025 CheckmAb S.r.l. announced today the successful achievement of the second milestone in the collaboration with Boehringer Ingelheim for the development of a monoclonal antibody (mAb) for cancer immunotherapy. Cancer immunotherapies have delivered meaningful therapeutic options to some cancer patients, [...]
DETAIL
Dec
01
EU funds research into causes and new therapies for multiple sclerosis
EU funds research into causes and new therapies for multiple sclerosis The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr virus is involved in the development of MS. However, it is not known how the pathogen triggers the [...]
DETAIL
Jan
18
“The junk DNA” is able to activate immune response of T lymphocytes, the guards of the fight against cancer”
The research, coordinated by Beatrice Bodega and Sergio Abrignani, has identified for the first time a new mechanism involving RNA molecules deriving from "repeated elements" of DNA: until a few years ago considered "junk DNA", they are instead fundamental for the correct function of T lymphocytes, cells at the forefront of the fight against cancer. [...]
DETAIL
Nov
22
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
On November 15, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), announced the agreement to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) discovered and developed jointly by IRBM, Promidis/CNCCS (a subsidiary of IRBM), Istituto [...]
DETAIL
Jul
27
New breakthrough to help immune systems in the fight against cancer
New research has identified potential treatment that could improve the human immune system’s ability to search out and destroy cancer cells within the body. Scientists have identified a way to restrict the activity a group of cells which regulate the immune system, which in turn can unleash other immune cells to attack tumours in cancer [...]
DETAIL
May
11
Merck ‘Grant for Oncology Innovation’ awards recognize recipients for pushing boundaries in oncology research
Merck today announced recipients of the fourth annual Grant for Oncology Innovation (GOI) awards. The three winners of this prestigious program were awarded €1 million in total to progress their research. Recipients of the 2017 GOI award are: Renata Maria Grifantini, National Institute of Molecular Genetics, Milan, Italy, for her proposal: “Novel targets of tumor-infiltrating CD4+ regulatory [...]
DETAIL
Mar
04
EMBL recognises the work of Raffaele De Francesco with the Lennart Philipson Award
The European Molecular Biology Laboratory (EMBL) has assigned the 2018 Lennart Philipson Award to Raffaele De Francesco, an EMBL alumnus now head of the Virology Laboratory of INGM. Raffaele De Francesco’s work on the Hepatitis C virus (HCV) led to a medical revolution. Previously, certain chronic viral infections had been kept under control using drugs, [...]
DETAIL
